Lung Cancer - Medical Oncology Clinical Trials Resources
Listed below are the Lung Cancer - Medical Oncology Clinical Trials offered at the Kaiser Permanente Santa Clara Medical Center.
| |
|
| |
|
| Title: |
Three Different Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide |
| Phase: |
III |
| Protocol Number: |
CALGB 30610 |
| Sponsors and Collaborators: |
CTSU |
| Weblink: |
Link to Clinical Trial |
| |
|
| Title: |
A RANDOMIZED PHASE II STUDY OF IMETELSTAT AS MAINTENANCE THERAPY AFTER INITIAL INDUCTION CHEMOTHERAPY FOR ADVANCE NON-SMALL CELL LUNG CANCER(NSCLC) |
| Phase: |
II |
| Protocol Number: |
CP14B012 |
| Sponsors and Collaborators: |
Geron Corporation |
| Weblink: |
Link to Clinical Trial |
| |
|
| Title: |
A PHASE III RANDOMIZED TRIAL OF ADJUVANT CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB FOR PATIENTS WITH COMPLETELY RESECTED STAGE IB (> 4CM)-IIIA NON-SMALL LUNG CANCER (NSCLC) |
| Phase: |
III |
| Protocol Number: |
E1505 |
| Sponsors and Collaborators: |
CTSU (Cancer Trial Support Unit) |
| Weblink: |
Link to Clinical Trial |
| |
|
| Title: |
A PHASE II SELECTION DESIGN OF PHARMACODYNAMIC SEPARATION OF CARBOPLATIN/PACLITAXEL/OSI-774 (ERLOTINIB; NSC-718781) OR OSI-774 ALONE IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH PERFORMANCE STATUS 2 (PS-2) SELECTED BY SERUM PROTEOMICS |
| Phase: |
II |
| Protocol Number: |
S0709 |
| Sponsors and Collaborators: |
SWOG (Southwest Oncology Group) |
| Weblink: |
Link to Clinical Trial |
| |
|
| Title: |
A Phase II Trial of the Combination of OSI-774 (ERLOTINIB; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) in Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features (ADENOBAC) |
| Phase: |
III |
| Protocol Number: |
SWOG-S0635 |
| Sponsors and Collaborators: |
Southwest Oncology Group
National Cancer Institute (NCI) |
| Weblink: |
Link to Clinical Trial |
| |
|
| Title: |
RANDOMIZED PHASE 3 TRIAL OF GEMCITABINE/CARBOPLATIN WITH OR WITHOUT BSI-201 (A PARP1 INHIBITOR) IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED SQUAMOUS CELL LUNG CANCER |
| Phase: |
III |
| Protocol Number: |
20090321 |
| Sponsors and Collaborators: |
BiPar Sciences
Sanofi-Aventis |
| Weblink: |
Link to Clinical Trial |
ONGOING STUDIES BUT CLOSED TO NEW PARTICIPANTS. |
| |
|
| Title: |
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF RECMAGE-A3 + AS15 ANTIGEN-SPECIFIC CANCER IMMUNOTHERAPEUTIC AS ADJUVANT THERAPY IN PATIENTS WITH RESPECTABLE MAGE-A3-POSITIVE NON-SMALL CELL LUNG CANCER. |
| Phase: |
III |
| Protocol Number: |
GSK 109493 |
| Sponsors and Collaborators: |
GlaxoSmithKline |
| Weblink: |
Link to Clinical Trial |
| |
|
| Title: |
MOLECULAR EPIDEMIOLOGY CASE-SERIES STUDY OF NON-SMALL CELL LUNG CANCER IN SMOKING AND NON-SMOKING WOMEN AND MEN |
| Phase: |
Not Applicable |
| Protocol Number: |
S0424 |
| Sponsors and Collaborators: |
SWOG (Southwest Oncology Group) |
| Weblink: |
Link to Clinical Trial |
| |
|
| Title: |
LUNG CANCER SPECIMEN REPOSITORY PROTOCOL, ANCILLARY |
| Phase: |
Not Applicable |
| Protocol Number: |
S9925 |
| Sponsors and Collaborators: |
SWOG (Southwest Oncology Group) |
| Weblink: |
Link to Clinical Trial |
| |
|
| Title: |
A PHASE II TRIAL OF THE COMBINATION OF OSI-774 (ERLOTINIB; NSC-718781) AND BEVACIZUMAB (RHUMAB VEGF; NSC 704865) IN NEVER-SMOKERS WITH STAGE IIIB AND IV PRIMARY NSCLC ADENOCARCINOMAS |
| Phase: |
II |
| Protocol Number: |
S0636 |
| Sponsors and Collaborators: |
SWOG (Southwest Oncology Group) |
| Weblink: |
Link to Clinical Trial |
| |
|
| Title: |
PHASE III BIOMARKER VALIDATION STUDY OF SECOND-LINE THERAPY IN PATIENTS WITH ADVANCED NON- SMALL CELL LUNG CANCER (NSCLC) RANDOMIZED TO PEMETREXED VERSUS ERLOTINIB |
| Phase: |
III |
| Protocol Number: |
N0723 |
| Sponsors and Collaborators: |
CTSU (Cancer Trial Support Unit) |
| Weblink: |
Link to Clinical Trial |
